RBF Symposium

February 1, 2011
07.00-08.45 hr	Registration
09.00 hr		Inauguration ceremony Keynote Address *A Nobel Prize by Chance!* Prof. (Dr.) Rolf Zinkernagel Nobel Laureate ( Medicine ) Zurich, Switzerland
11.00 hr	Tea/Coffee Break
Session I Chairperson Dr. Kapil Dhingra Retired Vice President, Head, Oncology Disease Biology Leadership Team, Roche Dr. Y. K. Gupta Professor & Head, Dept of Pharmacology, All India Institute of Medical Sciences, Delhi, India
12.00 hr		*Therapeutic Science and Medicine: New Models for Academic--Industry Interactions* Dr. William W. Chin, MD, PhD Executive Dean for Research Professor of Medicine Harvard Medical School Retired Senior Vice President, Discovery Research & Clinical Investigation, Eli Lilly, USA
12.45 hr		State of Oncology Therapeutic Research : A look ahead Dr. Kapil Dhingra Retired Vice President, Head, Oncology Disease Biology Leadership Team, Roche
13.10 hr	Lunch break / Poster Session
14.30 hr		Synthetic Lethality in Cancer Treatment: Current status of PARP Inhibitors Dr. Hilary Calvert, MD Director of Cancer Drug Discovery and Development, UCL Cancer Institute, London, UK
15.15 hr		*DNA repair dysfunctionality in lung cancer* Dr. Jean-Charles Soria, MD Institut Gustave Roussy, Head of the Early Therapeutics Innovations Service (SITEP), Villejuif, France
16.00 hr	Tea/Coffee Break
16.30 hr		Outliers, Invisible Gorillas, and Fellow Travelers-Understanding the Difference for Molecularly Targeted Drug Development Dr. Anthony W. Tolcher, MD Director of START (South Texas Accelerated Research Therapeutics) and Clinical Professor of Medicine in the Division of Medical Oncology, University of Texas Health Science Center, San Antonio, USA
17.15 hr		*PI3 Kinase inhibitor for the treatment of cancer* Dr. Pablo Cagnoni, MD SVP Global Head, Clinical Development, Novartis Pharmaceuticals, Switzerland
18.00 hr	Panel Discussion	Dr. Kapil Dhingra Dr. Rolf Zinkernagel Dr. William W. Chin Dr. Hilary Calvert Dr. Jean-Charles Soria Dr. Anthony W. Tolcher Dr. Pablo Cagnoni

February 2, 2011
Session II Chairperson Dr. Hilary Calvert, MD Director of Cancer Drug Discovery and Development, UCL Cancer Institute, London, UK Dr. S. D. Seth Advisor, Indian Council of Medical Research
09.00 hr		*Harnessing the immune system to treat cancer – A reality at last* Dr. Kapil Dhingra Retired Vice President, Head, Oncology Disease Biology Leadership Team, Roche
09.45 hr		*Manipulating the Inhibitory Arm of the Immune System, a Needed Strategy for Cancer Therapy* Dr. Samir N. Khleif, M.D. Head, Cancer Vaccine Section, Investigator, National Cancer Institute Bethesda, USA
10.30 hr		*T cell-engaging BiTE antibodies for cancer therapy* Dr. Patrick Baeuerle, PhD Chief Scientific Officer, Micromet
11.15 hr	Tea/Coffee Break
11.45 hr		Oncology Clinical Research : India Prof. Vinod Raina, MD, FRCP. Head Dept of Medical Oncology & Head Delhi Cancer Registry Institute of Rotary Cancer Hospital All India Institute of Medical Sciences (AIIMS)
12.30 hr		*Targeting Multiple Myeloma: Use of Translational Research to Inform a Development Path for the KSP inhibitor ARRY-520* Dr. Duncan Walker, PhD Senior Director, Translational Medicine, Array Biopharma, USA
13.15 hr	Lunch Break / Poster Session
Session III Chairperson Dr. Pankaj Shah Director, Gujarat Cancer Research Institute Dr. J. S. Yadav Director, Indian Institute of Chemical Technology
15.00 hr		*Estrogen receptor beta-selective compounds and their potential role in cancer therapy* Anneli Hallgren CSO, Karobio Sweden
15.45 hr		*Cancer Metabolism: The Warburg Effect Revisited* Dr. Rajesh Chopra MD, PhD Vice President Translational Development, Celgene, USA
16.30 hr	Tea/Coffee Break
17.00 hr		*From Fragment to clinic: Translational biomarkers for clinical candidates derived from fragment-based drug design.* Dr. John Lyons, MSc PhD, VP Translational Research & Development, Astex Pharma
17.45 hr		*'Innovation management in drug discovery'* Dr. Mikio Arisawa Retd. Head of Discovery, Chugai (Roche Group), Japan
18.30 hr	*Panel discussion*	Dr. Kapil Dhingra Dr. Samir N. Khleif Dr. Patrick Beauerle Dr. Anneli Hallgren Dr. Duncan Walker Dr. Rajesh Chopra Dr. Mikio Arisawa Dr. Vinod Raina
19.00 hr	Workshop by Cambridgesoft Corp. Informatics solution for Research, Cambridgesoft Corp, USA
19.30 hr	Workshop by Biotron Healthcare HTRF chemistry and applications in drug discovery Roderick Haroutunian, CIS BIO, France BMG omega / PHERAstar: new standard for multi lable detection John Abbenante, BMG Lab Tech Australia
20.00 hr	Workshop by GE Healthcare Modern Bioanalytics- Getting closer to understanding your product Mr. Lalith Kishore, GE Healthcare

February 3, 2011
Session IV Chairperson Dr. Richard DiMarchi, PhD Gill Professor of Biochemistry, Indiana University, USA Dr. John Amatruda, MD, Retired Merck Sr. VP & Franchise Head, Diabetes/Obesity, USA
09.00 hr		*New Therapies for the Treatment of Type II Diabetes: Challenges and Opportunities* Nancy Thornberry Sr. VP, Metabolic Franchise Head, Merck Research Labs, USA
09.45 hr		*CNS Integration of Systems Metabolism: Target Opportunities for Diabetes Prevention and Therapy* Dr. Matthias Tschoep, MD Professor of Endocrinology, University of Cincinnati, USA
10.30 hr	Tea/Coffee Break
11.00 hr		*MicroRNAs: Function in metabolism and therapeutic opportunities* Dr. Markus Stoffel, MD Professor, ETH Zurich Institute of Molecular Systems Biology Zurich, Switzerland
11.45 hr		*Insights into insulin resistance from metabolomics analysis following bariatric surgery* Dr. Charles Burant, MD, PhD Atkins Professor of Metabolism, University of Michigan, USA
12.30 hr	Lunch Break / Poster session
Session V Chairperson Nancy Thornberry Sr. VP, Metabolic Franchise Head, Merck Research Labs, USA Dr. Gianni Gromo Sr. VP and Global Head, Metabolic & Vascular Disease Area, Roche, Switzerland
14.00 hr		*Dissecting Hypothalamic Signaling: Targeting Metabolic Disease* Dr. Jens C. Bruning, MD Institute of Genetics, University of Cologene, Germany
14.45 hr		*The dynamic interaction between food, brain and body mass index* Dr. Dana Small, PhD Associate Professor, Department of Psychiatry Yale University School of Medicine and Associate Fellow, The John B Pierce Laboratory, USA
15.30 hr	Tea/Coffee Break / Poster Session
16.00 hr		ZYOG1: A Novel Oral GLP-1 agonist for treatment of Type 2 Diabetes Dr. Mukul R. Jain, PhD Sr. VP, Zydus Research Center, Ahmedabad, India
16.45 hr		Structure-based design of biotherapeutics with enhanced solubility and bio-stability Dr. Faming Zhang, PhD CEO, Waterstone Pharmaceuticals Inc., USA.
17.30 hr		Expectations of India from global scientific community Dr. V. M. Katoch Secretary, Department of Health Research, Government of India & Director-General, Indian Council of Medical Research, India
17.50 hr	Panel Discussion	Dr. Richard DiMarchi Nancy Thornberry Dr. Matthias Tschoep Dr. Markus Stoffel Dr. Charles Burant Dr. Jens C. Bruning Dr. Dana Small Dr. Mukul R. Jain Dr. Faming Zhang Dr. V. M. Katoch
19.00 hr	Cultural Program Venue : Hotel Courtyard Marriot Ramdev Nagar Cross Roads, Satellite, Ahmedabad

February 4, 2011
Session VI Chairperson Dr. Charles Burant, MD, PhD Atkins Professor of Metabolism, University of Michigan, USA Dr. T. K. Chakraborty Director, Central Drug Research Institute
09.00 hr		*The past, present and the future of Cardiovascular translational medicine research* Dr. Gianni Gromo Sr. VP and Global Head, Metabolic & Vascular Disease Area, Roche, Switzerland
09.45 hr		Should Safety, Drug Exposure and Clinical Efficacy of Diabetes Drugs Be Assessed in Patients or in Healthy Volunteers? Dr. Marcus Hompesch, President - CEO Profil Institute for Clinical Research Inc. California, USA
10.30 hr		“A prospective, multi-centric, open-label, single arm study to evaluate the safety and efficacy of 4mg of ZYH1 in hypertriglyceridemia in HIV associated lipodystrophy” Dr. Dhiraj Gambhire, MD Cadila Healthcare Ltd, Mumbai, India
11.15 hr	Tea/Coffee Break / Poster Session
11.45 hr		*Big Pharma: Leveraging for an Efficient R&D Organization* Dr. John Amatruda, MD, Retired Merck Sr. VP & Franchise Head, Diabetes/Obesity, USA
12.30 hr		*Development of Prodrug Chemistry Suitable for Application to Therapeutic Peptides* Dr. Richard DiMarchi, PhD Gill Professor of Biochemistry, Indiana University, USA Retired Executive VP, Lilly Research Labs., Indianapolis, USA
13.15 hr	Lunch Break
14.30 hr		*Treatment of Metabolic Diseases with Proteins Site-Specifically Optimized for Pharmacological Use* Dr. Douglas W. Axelrod, MD, PhD Chief Medical Officer Senior Vice President, Development Ambrx, Inc.
15.15 hr		Liver Selective Glucokinase Activation for Treating Type 2 Diabetes: Translation from Mouse to Man Kasim A. Mookhtiar, Ph.D. Chief Scientific Officer and EVP, Drug Discovery Advinus Therapeutics Pvt Ltd, Pune, India
16.00 hr	Panel Discussion	Dr. Richard DiMarchi Dr. John Amatruda Dr. Gianni Gromo Dr. Marcus Hompesch Dr. Douglas W. Axelrod Dr. Kasim A. Mookhtiar
16.30 hr		Best Posters Award Three selected posters will be announced for prize presentation. Time of 10 mins each will be provided to the 3 best posters for podium presentation.
17.00 hr	Wrap-up session